Clever Leaves Holdings Inc Quick Ratio (CLVR) starting from the fourth quarter 2023 to fourth quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Clever Leaves Holdings Inc   (NASDAQ: CLVR)

Clever Leaves Holdings Inc 's Quick Ratio

CLVR's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Clever Leaves Holdings Inc 's Cash & cash equivalent grew by 5.55 % in the Q4 2023 sequentially, while Current Liabilities decreased, this led to improvement in Clever Leaves Holdings Inc 's Quick Ratio to 1.18, Quick Ratio remained below Clever Leaves Holdings Inc average.

Within Major Pharmaceutical Preparations industry 209 other companies have achieved higher Quick Ratio than Clever Leaves Holdings Inc in fourth quarter 2023. While Quick Ratio total ranking in the fourth quarter 2023 has deteriorated compared to the prior quarter from 1190 to 1242.

Explain Quick Ratio?
How much Cash & cash equivalents CLVR´s has?
What are CLVR´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CLVR Quick Ratio (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4
Y / Y Current Liabilities Change -38.35 % -16.68 % -12.52 % -71.62 % -65.4 %
Y / Y Cash & cash equivalent Change -45.13 % -62.33 % -73.31 % -85.64 % -66.56 %
Quick Ratio MRQ 1.18 0.95 0.67 0.82 1.32
CLVR's Total Ranking # 1242 # 1190 # 1713 # 1825 # 1499
Seq. Current Liabilities Change -15.13 % -9.46 % -3.09 % -17.22 % 14.7 %
Seq. Cash & cash equivalent Change 5.55 % 27.48 % -20.2 % -48.9 % -27.55 %



Quick Ratio fourth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 210
Healthcare Sector # 408
Overall Market # 1242


Quick Ratio Statistics
High Average Low
2.2 1.33 0.67
(Jun 30 2022)   (Jun 30 2023)




Financial Statements
Clever Leaves Holdings Inc 's Current Liabilities $ 6 Millions Visit CLVR's Balance sheet
Clever Leaves Holdings Inc 's Cash & cash equivalent $ 7 Millions Visit CLVR's Balance sheet
Source of CLVR's Sales Visit CLVR's Sales by Geography


Cumulative Clever Leaves Holdings Inc 's Quick Ratio

CLVR's Quick Ratio for the trailling 12 Months

CLVR Quick Ratio

 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months
Y / Y Current Liabilities TTM Growth -47.9 % -55.81 % -65.63 % -76.32 % -55.15 %
Y / Y Cash & cash equivalent TTM Growth -73.39 % -74.22 % -71.93 % -70.09 % -55.37 %
Quick Ratio TTM 0.88 0.96 1.24 1.61 1.73
Total Ranking TTM # 3952 # 1396 # 3276 # 3868 # 3665
Seq. Current Liabilities TTM Growth -11.43 % -4.15 % -3.17 % -36.61 % -24.89 %
Seq. Cash & cash equivalent TTM Growth -18.5 % -26.08 % -25.35 % -40.82 % -21.04 %

Quick ratio ranking by company, industry and sector >> Back to CLVR Financial Strength Comparisons >> Go to Compare CLVR Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in CLVR's Current Liabilities to $5.81 millions, cumulative Quick Ratio to 0.88 below the CLVR average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 484 other companies have achieved higher Quick Ratio than Clever Leaves Holdings Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2023 from 1396 to 3952.

Explain Quick Ratio?
How much Cash & cash equivalents CLVR´s has?
What are CLVR´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 485
Healthcare Sector # 985
Within the Market # 3952


trailing twelve months Quick Ratio Statistics
High Average Low
1.73 1.32 0.88
(Dec 31 2022)   (Dec 31 2023)




Companies with similar Quick Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2023 MRQ Cash & cash equivalentDec 31 2023 MRQ Current Liabilities
Travere Therapeutics Inc   3.19 $ 566.851  Millions$ 177.908  Millions
Actinium Pharmaceuticals Inc  3.18 $ 76.677  Millions$ 24.125  Millions
Deciphera Pharmaceuticals Inc   3.16 $ 306.216  Millions$ 96.771  Millions
Corcept Therapeutics Inc  3.13 $ 368.221  Millions$ 117.527  Millions
Alaunos Therapeutics Inc   3.10 $ 6.062  Millions$ 1.956  Millions
Geron Corporation  3.10 $ 334.814  Millions$ 108.070  Millions
Edesa Biotech Inc   3.06 $ 5.400  Millions$ 1.762  Millions
Adagene Inc   3.03 $ 111.725  Millions$ 36.885  Millions
Polomar Health Services, Inc.  3.02 $ 0.226  Millions$ 0.075  Millions
Xilio Therapeutics Inc   3.00 $ 44.704  Millions$ 14.910  Millions
Quoin Pharmaceuticals Ltd   2.99 $ 10.701  Millions$ 3.582  Millions
Assembly Biosciences Inc   2.98 $ 130.247  Millions$ 43.720  Millions
Zomedica Corp   2.92 $ 12.952  Millions$ 4.436  Millions
Karyopharm Therapeutics Inc   2.90 $ 192.103  Millions$ 66.171  Millions
Revance Therapeutics Inc   2.88 $ 254.465  Millions$ 88.263  Millions
Genelux Corporation  2.87 $ 23.191  Millions$ 8.080  Millions
Urogen Pharma Ltd   2.86 $ 95.055  Millions$ 33.186  Millions
Hepion Pharmaceuticals Inc   2.86 $ 14.786  Millions$ 5.174  Millions
Cue Biopharma Inc   2.84 $ 48.514  Millions$ 17.081  Millions
Mannkind Corporation  2.83 $ 295.099  Millions$ 104.125  Millions
Longeveron Inc   2.83 $ 9.325  Millions$ 3.296  Millions
Regulus Therapeutics Inc   2.80 $ 23.800  Millions$ 8.508  Millions
Axsome Therapeutics Inc   2.78 $ 386.193  Millions$ 138.854  Millions
Arrowhead Pharmaceuticals Inc   2.78 $ 292.735  Millions$ 105.456  Millions
G1 Therapeutics Inc   2.76 $ 82.156  Millions$ 29.716  Millions
Mersana Therapeutics inc   2.74 $ 174.561  Millions$ 63.637  Millions
Precigen Inc   2.73 $ 62.855  Millions$ 22.985  Millions
Cyclerion Therapeutics Inc   2.73 $ 7.571  Millions$ 2.771  Millions
Vertex Pharmaceuticals Inc  2.69 $ 11,218.300  Millions$ 4,163.300  Millions
Kuvatris Therapeutics Inc   2.62 $ 4.711  Millions$ 1.795  Millions

Date modified: 2026-09-08T15:22:12+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.